Survodutide Research for MASH/NAFLD

Phase 2 RCT (N=293) showed up to 62% MASH improvement without worsening of fibrosis vs 14% placebo, and up to 36% fibrosis improvement (>=1 stage) vs 22% placebo at 48 weeks. A >=30% reduction in liver fat occurred in 57-67% of survodutide groups vs 14% placebo. The phase 3 SYNCHRONIZE-MASLD trial (n=216, 48 weeks) then met both co-primary endpoints: on the treatment-regimen estimand, 68.5% of survodutide-treated participants versus 28.6% on placebo achieved a >=30% reduction in MRI-PDFF liver fat, with mean body-weight change of -8.7% versus -1.4%.